Volume 29, Issue 3
DOI: 10.24205/03276716.2020.917
Montelukast Combined with Loratadine can Improve The Immune Function and SF-36 Score of Patients with Allergic Rhinitis
Abstract
Objective: To determine the influence of montelukast combined with loratadine on the immune function and MOS 36-Item Short-Form Health Survey (SF-36) score of patients with allergic rhinitis.
Methods: Patients with allergic rhinitis admitted to our hospital between December 2018 and December 2019 were selected and randomly assigned to a control group (con group) and an observation group (obs group). Patients in the con group were treated with loratadine alone, while those in the obs group were treated with montelukast combined with loratadine. The therapeutic effect, nasal symptom scores, changes in immune function-related indexes, and life quality SF-36 score of the two groups were evaluated. Results: Before treatment, no remarkable difference was found in nasal symptom scores between the two groups, while after treatment, the nasal symptom scores of the obs group were significantly better than those of the con group, and the effective treatment rate of the obs group was greatly higher than that of the con group. In addition, the changes of immune function indexes in the obs group were also significantly better than those in the con group, and the obs group experienced significantly higher life quality than the con group after treatment. Moreover, there no remarkable difference was found between the two groups in the incidence of adverse reactions (P> 0.05).
Conclusion: Montelukast combined with loratadine can provide relatively high efficacy on patients with allergic rhinitis and can ameliorate the immune function and life quality of the patients.
Keywords
Montelukast, loratadine, allergic rhinitis, immune function, life quality